← All trials
NCT04634877
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 18, 2020
- Primary completion
- Jun 18, 2025
- Completion date
- Jun 18, 2025
- First posted
- Nov 18, 2020
- Last posted
- Nov 23, 2020
- Enrollment
- 990
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- MerckLead sponsor
- MerckStudy director
- Gynecologic Oncology GroupCollaborator
- European Network for Gynaecological Oncological Trial GroupsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.